VANCOMYCIN MODIFICATION
ID: SPE2D217D0059P00005Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

Original Source

https://sam.gov/opp/c053567b91f64bce80f8837aaedd0f2f/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE is seeking VANCOMYCIN MODIFICATION services. VANCOMYCIN MODIFICATION P00005 is a contract modification that incorporates additional clauses into the existing contract. VANCOMYCIN is an antibiotic used to treat serious bacterial infections. The DEPT OF DEFENSE is looking to modify the contract to include these additional clauses.

    Files
    Title
    Posted
    SPE292-17-D-0059 P0006 signed.pdf
    SPE2D217D0059P00005 SIGNED.pdf
    SPE2D217D0059P00007.pdf
    SPE2D217D0059P00008 signed.pdf
    Lifecycle
    Title
    Type
    VANCOMYCIN MODIFICATION
    Currently viewing
    Special Notice
    Similar Opportunities
    Fluconazole - Modification P00005 to Contract
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY - TROOP SUPPORT MEDICAL is seeking a modification to the contract for Fluconazole. Fluconazole is a medication used to treat and prevent fungal infections. The modification, P00005, will involve changing the National Drug Codes (NDCs) associated with the procurement.
    LANSOPRAZOLE NATIONAL CONTRACT MODIFICATION
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is issuing a modification to the LANSOPRAZOLE NATIONAL CONTRACT. This modification aims to incorporate additional clauses to the existing contract. Lansoprazole is a medication used to treat stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). It belongs to a class of drugs known as proton pump inhibitors and helps reduce the amount of acid produced in the stomach. The modification to the contract will include the addition of specific clauses that may address various aspects such as pricing, delivery schedules, quality control, or any other relevant terms and conditions. For more information or inquiries, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 2157378677.
    MODIFICATION TO ENALAPRIL NATIONAL CONTRACT
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking a modification to the ENALAPRIL NATIONAL CONTRACT. This modification aims to incorporate additional clauses into the existing contract. The ENALAPRIL NATIONAL CONTRACT is typically used for the procurement of enalapril, a medication used to treat high blood pressure and heart failure. The modification will ensure that the contract includes all necessary terms and conditions for the procurement of enalapril. For more information, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.
    6505--Mycophenolate Mofetil RFP
    Buyer not available
    The Department of Veterans Affairs is seeking proposals for the procurement of Mycophenolate Mofetil capsules and tablets under Solicitation Number 36E79725R0010, aimed at establishing national pricing for these pharmaceutical products. The contract is intended to support various government health care facilities, including those under the Department of Defense and Indian Health Service, ensuring compliance with FDA standards and the Drug Supply Chain Security Act. Offerors are required to submit pricing for both the base year and four option years, with a deadline for submissions extended to March 4, 2025, at 2:30 PM CST, and must acknowledge receipt of this amendment to avoid rejection of their offers. Interested parties can contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further information.
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    6505--Bevacizumab Injection
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Bevacizumab injections, a critical pharmaceutical product used in various healthcare settings for veterans. Vendors are required to meet specific criteria, including providing unique National Drug Codes (NDC) and adhering to the Drug Supply Chain Security Act regulations, as the contract aims to ensure a reliable supply of this medication across government health care facilities. The selected contractor will be responsible for multiple line items of different Bevacizumab formulations, maintaining compliance with FDA manufacturing practices, and submitting quarterly sales reports, including cost recovery fees. Interested vendors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details, with submissions due by the specified deadlines outlined in the solicitation document.
    Fexofenadine HCL Follow On MOD P00002
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    MODIFICATION TO CONTRACT
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is modifying a contract with DLA TROOP SUPPORT. The modification to the contract is the focus of this notice.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents as part of its Pharmacy Uniform Formulary Blanket Purchase Agreement and Additional Discount Program, managed by the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the selection and classification of pharmaceutical agents based on clinical and cost-effectiveness for military beneficiaries. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review specific drug classes, including Breast Cancer Agents and Targeted Immunomodulatory Biologics, with quotes due by March 20, 2025. Interested vendors should direct inquiries to Tracy Banks at tracy.e.banks2.civ@health.mil or Julianne Canaley at julianne.m.canaley.ctr@health.mil for further details.